Endoscopic retrograde cholangiopancreatography in cirrhosis - a systematic review and meta-analysis focused on adverse events

Harmeet Singh Mashiana; Amaninder Singh Dhaliwal; Harlan Sayles; Banreet Dhindsa; Ji Won Yoo; Qing Wu; Shailender Singh; Ali A Siddiqui; Gordon Ohning; Mohit Girotra; Douglas G Adler

doi:10.4253/wjge.v10.i11.354

Endoscopic retrograde cholangiopancreatography in cirrhosis - a systematic review and meta-analysis focused on adverse events

World J Gastrointest Endosc. 2018 Nov 16;10(11):354-366. doi: 10.4253/wjge.v10.i11.354.

Authors

Affiliations

¹ Department of Internal Medicine, University of Nevada Las Vegas School of Medicine, Las Vegas, NV 89102, United States.
² Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, 982000 Nebraska Medical Center, Omaha, NE 68198-2000, United States.
³ Department of Biostatistics, University of Nebraska Medical Center, 982000 Nebraska Medical Center, Omaha, NE 68198-2000, United States.
⁴ Nevada Institute of Personalized Medicine, Department of Environmental and Occupational Health, School of Community Health Sciences, University of Nevada, Las Vegas, NV 89154-4009, United States.
⁵ Division of Gastroenterology, Jefferson Medical College, Philadelphia, PA 19107, United States.
⁶ Division of Gastroenterology, University of Nevada Las Vegas School of Medicine, Las Vegas, NV 89102, United States.
⁷ Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, FL 33136, United States.
⁸ Division of Gastroenterology and Hepatology, University of Utah School of Medicine, Huntsman Cancer Center, Salt Lake City, UT 84132, United States. douglas.adler@hsc.utah.edu.

Abstract

Aim: To investigate indications and outcomes of endoscopic retrograde cholangiopancreatography (ERCP) in cirrhotics, especially adverse events. Patients with cirrhosis undergoing ERCP are believed to have increased risk. However, there is a paucity of literature describing the indications and outcomes of ERCP procedures in patients with cirrhosis, especially focusing on adverse events.

Methods: We performed a systematic appraisal of major literature databases, including PubMed and EMBASE, with a manual search of literature from their inception until April 2017.

Results: A total of 6,505 patients from 15 studies were analyzed (male ratio 59%, mean age 59 years), 11% with alcoholic and 89% with non-alcoholic cirrhosis, with 56.2% Child-Pugh class A, and 43.8% class B or C. Indications for ERCP included choledocholithiasis 60.9%, biliary strictures 26.2%, gallstone pancreatitis 21.1% and cholangitis 15.5%. Types of interventions included endoscopic sphincterotomy 52.7%, biliary stenting 16.7% and biliary dilation 4.6%. Individual adverse events included hemorrhage in 4.58% (95%CI: 2.77-6.75%, I ² = 85.9%), post-ERCP pancreatitis (PEP) in 3.68% (95%CI: 1.83-6.00%, I ² = 89.5%), cholangitis in 1.93% (95%CI: 0.63-3.71%, I ² = 87.1%) and perforation in 0.00% (95%CI: 0.00-0.23%, I ² = 37.8%). Six studies were used for comparison of ERCP-related complications in cirrhosis vs non-cirrhosis, which showed higher overall rates of complications in cirrhosis patients with pooled OR of 1.63 (95%CI: 1.27-2.09, I ² = 65%): higher rates of hemorrhage with OR of 2.05 (95%CI: 1.62-2.58, I ² = 2.1%) and PEP with OR of 1.33 (95%CI: 1.04-1.70, I ²=65%), but similar cholangitis rates with OR of 1.23 (95%CI: 0.67-2.26, I ² = 44.3%).

Conclusion: There is an overall higher rate of adverse events related to ERCP in patients with cirrhosis, especially hemorrhage and PEP. A thorough risk/benefit assessment should be performed prior to undertaking ERCP in patients with cirrhosis.

Keywords: Adverse events; Cirrhosis; Endoscopic retrograde cholangiopancreatography; Meta-analysis; Systematic review.